Web References

7. Zhang W et al., Pharmacokinetic, pharmacodynamic, and safety evaluation of single and multiple 60mg, 90mg, and 120mg oral doses of modified release TAK-390 (TAK-390MR) and 30mg oral doses of lansoprazole in healthy subjects. Gastroenterology 2007; 132(suppl 52):A487. Abstract
12. Takepron Hong Kong package insert (TKP0711HK1) [available upon request]
15. Dabholkar HA et al., The 12-month safety profile of dexlansoprazole, a proton pump inhibitor with dual delayed release formulation, in patients with gastro-oesophageal reflux disease. Aliment Pharmacol Ther;2011;33:366-377
18. Howden CW et al., Clinical trial: efficacy and safety of dexlansoprazole MR60 and 90mg in healed erosive oesophagitis – maintenance of healing and symptom relief. Aliment Pharmacol Ther 2009;30:895-907
23. Package Insert – Dexlansoprazole (Dexilant®). Takeda. DEX0912PIHK